Antireflux mucosectomy (ARMS) and antireflux mucosal ablation (ARMA) for gastroesophageal reflux disease: a systematic review and meta-analysis

Abstract

Background and study aims Antireflux mucosectomy (ARMS) and antireflux mucosal ablation (ARMA) are new endoscopic procedures for patients with gastroesophageal reflux disease (GERD). We conducted a meta-analysis to systematically assess the feasibility, clinical success, and safety of these procedures.

Patients and methods We searched Embase, PubMed, and Cochrane Central from inception to October 2020. Overlapping reports, animal studies, and case reports were excluded. Our primary outcomes were clinical success and adverse events (AEs). Secondary outcomes included technical success, endoscopic esophagitis, 24-hour pH monitoring, and proton pump inhibitor (PPI) use. A random effects model was used to pool data.

Results In total, 15 nonrandomized studies (12 ARMS, n = 331; 3 ARMA, n = 130) were included; 10 were conducted in patients with refractory GERD. The technical success rate was 100 %. The pooled short-term (first assessment within the first 6 months), 1-year, and 3-year clinical success rates were 78 % (95 % confidence interval [95 %CI] 70 %–85 %), 72% (95 %CI 47 %–92 %), and 73 % (95 %CI 65 %–81 %), respectively. ARMS and ARMA yielded similar clinical success. The proportion of patients off PPIs at 1 year was 64 % (95 %CI 52 %–75 %). There were significant drops (P < 0.01) in validated clinical questionnaires scores, presence of esophagitis, and acid exposure time. The most common AE (11 %, 95 %CI 8 %–15 %) was dysphagia requiring dilation (7%, 95 %CI 5 %–11 %). Four cases of perforation were recorded, all in patients undergoing ARMS.

Conclusions Our meta-analysis of nonrandomized studies suggests that ARMS and ARMA are safe and effective for patients with GERD.

Publikationsverlauf

Eingereicht: 17. April 2021

Angenommen: 09. Juli 2021

Artikel online veröffentlicht:
12. November 2021

• References

• 1 Eusebi LH, Ratnakumaran R, Yuan Y. et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut 2018; 67: 430-440
• 2 GBD 2017 Gastro-oesophageal Reflux Disease Collaborators. The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020; 5: 561-581
• 3 Yadlapati R, Vaezi MF, Vela MF. et al. Management options for patients with GERD and persistent symptoms on proton pump inhibitors: recommendations from an expert panel. Am J Gastroenterol 2018; 113: 980-986
• 4 de la Coba Ortiz C, Argüelles Arias F, Martín de Argila de Prados C. et al. Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Española de Patología Digestiva. Rev Esp Enferm Dig 2016; 108: 207-224
• 5 Singhal S, Kirkpatrick DR, Masuda T. et al. Primary and redo antireflux surgery: outcomes and lessons learned. J Gastrointest Surg 2018; 22: 177-186
• 6 Weusten BLAM, Barret M, Bredenoord AJ. et al. Endoscopic management of gastrointestinal motility disorders – part 2: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2020; 52: 600-614
• 7 Inoue H, Ito H, Ikeda H. et al. Anti-reflux mucosectomy for gastroesophageal reflux disease in the absence of hiatus hernia: A pilot study. Ann Gastroenterol 2014; 27: 346-351
• 8 Inoue H, Tanabe M, de Santiago ER. et al. Anti-reflux mucosal ablation (ARMA) as a new treatment for gastroesophageal reflux refractory to proton pump inhibitors: a pilot study. Endosc Int Open 2020; 8: E133-E138
• 9 Hernández Mondragón OV, Zamarripa Mottú RA, García Contreras LF. et al. Clinical feasibility of a new antireflux ablation therapy on gastroesophageal reflux disease (with video). Gastrointest Endosc 2020; 92: 1190-1201
• 10 Yoo I, Ko WJ, Kim HS. et al. Anti-reflux mucosectomy using a cap-assisted endoscopic mucosal resection method for refractory gastroesophageal disease: a prospective feasibility study. Surg Endosc 2020; 34: 1124-1131
• 11 Bapaye A, Mahadik M, Pujari R. et al. Anti-reflux mucosectomy (ARMS) for refractory GERD-Initial clinical experience. J Gastroenterol Hepatol 2017; 32: 255
• 12 Monino L, Gonzalez JM, Vitton V. et al. Antireflux mucosectomy band in treatment of refractory gastroesophageal reflux disease: A pilot study for safety, feasibility and symptom control. Endosc Int Open 2020; 8: E147-E154
• 13 Ma L-L, Wang Y-Y, Yang Z-H. et al. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?. Mil Med Res 2020; 7: 7
• 14 Higgins JP, Thomas J, Chandler J. et al. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019
• 15 Barendregt JJ, Doi SA, Lee YY. et al. Meta-analysis of prevalence. J Epidemiol Community Health 2013; 67: 974-978
• 16 Wan X, Wang W, Liu J. et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135
• 17 Spechler SJ, Hunter JG, Jones KM. et al. Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. N Engl J Med 2019; 381: 1513-1523
• 18 Sumi K, Inoue H, Kobayashi Y. et al. Endoscopic treatment of proton pump inhibitor-refractory gastroesophageal reflux disease with anti-reflux mucosectomy: Experience of 109 cases. Dig Endosc 2020;
• 19 Patil G, Dalal A, Maydeo A. Feasibility and outcomes of anti-reflux mucosectomy for proton pump inhibitor dependent gastroesophageal reflux disease: First Indian study (with video). Dig Endosc 2020; 32: 745-752
• 20 Debourdeau A, Vitton V, Monino L. et al. Antireflux Mucosectomy Band (ARM-b) in treatment of refractory gastroesophageal reflux disease after bariatric surgery. Obes Surg 2020; 30: 4654-4658
• 21 Ota K, Takeuchi T, Harada S. et al. A novel endoscopic submucosal dissection technique for proton pump inhibitor-refractory gastroesophageal reflux disease. Scand J Gastroenterol 2014; 49: 1409-1413
• 22 Wong HJ, Su B, Attaar M. et al. Anti-reflux mucosectomy (ARMS) results in improved recovery and similar reflux quality of life outcomes compared to laparoscopic Nissen fundoplication. Surg Endosc 2020;
• 23 Vasilevskiy DI, Bagnenko SF, Smirnov A. et al. Antireflux mucosectomy (Arms) in the treatment of patients with gerd and columnar-cell lined (barrett’s) esophagus. First experiences. Surg Endosc 2017; 31: S405
• 24 Shah R, Maydeo AP, Dhir V. Anti reflux mucosectomy (ARMS) for refractory gastro esophageal reflux disease (GERD)-are we there yet?. United European Gastroenterol J 2017; 5: A354-A355
• 25 Ortega A, Rosón P, Fern F. et al. Antireflux mucosectomy. preliminary results of a prospective study. Endoscopy 2019; 51: S240-S241
• 26 Mohan PrasadVG, Appadurai S, Suman MP. Anti-reflux mucosectomy (ARMS) for refractory GERD-Our 3yrs experience. J Gastroenterol Hepatol 2019; 34: 232
• 27 Hernández Mondragón OV, Pintor JC, Gutierrez Aguilar RA. et al. Antireflux ablation therapy (ARAT), for reflux disease after poem procedure. Early clinical experience. Gastrointest Endosc 2020; 91: AB130
• 28 Fass R, Cahn F, Scotti DJ. et al. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease. Surg Endosc 2017; 31: 4865-4882
• 29 Garg SK, Gurusamy KS. Laparoscopic fundoplication surgery versus medical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev; 2015: CD003243
• 30 Li X, Zhang W, Chen M. et al. A Prospective randomized trial to assess the antireflux effect of antireflux mucosectomy in the porcine model. Gastroenterol Res Pract 2019;
• 31 McCarty TR, Itidiare M, Njei B. et al. Efficacy of transoral incisionless fundoplication for refractory gastroesophageal reflux disease: a systematic review and meta-analysis. Endoscopy 2018; 50: 708-725
• 32 Schuitenmaker JM, van Hoeij FB, Schijven MP. et al. Pneumatic dilation for persistent dysphagia after antireflux surgery, a multicentre single-blind randomised sham-controlled clinical trial. Gut 2021;
• 33 Cremonini F, Ziogas DC, Chang HY. et al. Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010; 32: 29-42